



# Pharmacy and Therapeutics Committee

July 17, 2018 12:00pm -5:00 pm  
Gold Room, 3<sup>rd</sup> Floor  
701 E. Jefferson Phoenix, AZ 85034

## AGENDA

Teleconference: 1-877-820-7831 Passcode: 960711

### Agenda Topics

Noon

**Welcome and Introductions:** Sara Salek, MD, Chief Medical Officer, AHCCCS

- April 17, 2018 P&T Minutes Review and Vote
- P&T Purpose and Operational Policy
- AHCCCS Drug Lists

### AHCCCS and Behavioral Health Drug Lists

12:15PM

**Supplemental Rebate Class Review:**

1. Oral Atypical (Second Generation) Antipsychotics
  - a. Clinical review:, Magellan
  - b. Pharma Testimony:
    - i. Abilify MyCite: Kristin Pareja, Otsuka
    - ii. Rexulti: Kristin Pareja, Otsuka
    - iii. Vraylar: Phillip Jennings, Allergan
  - c. Public Testimony:
    - i. Erin Callinan
    - ii. Austin Kirkbride
    - iii. Danica Oparnica
2. Long-Acting Injectable Antipsychotics
  - a. Clinical review: Magellan
  - b. Pharma Testimony:
    - i. Abilify Maintena; Kristin Pareja, Otsuka
    - ii. Aristada; Kenneth Berry, Alkermes
    - iii. Invega Sustena: Danny McNatty, Janssen
    - iv. Trinza: Danny McNatty, Janssen
  - c. Public Testimony:
    - i. John Sarris, MD
    - ii. Carol Olson, DO
3. Stimulants & Related Agents
  - a. Clinical review: Magellan
  - b. Pharma Testimony:
    - i. Methylphenidate 72mg; Mitch Rice, Vertical Pharmaceuticals
  - c. Public Testimony:
4. Pancreatic Enzymes
  - a. Clinical review: Magellan
  - b. Pharma Testimony:
  - c. Public Testimony: None
5. Anticoagulants
  - a. Clinical review: Magellan

	<p>b. Pharma Testimony:</p> <p>i. Eliquis: Jon Glover, Pfizer</p> <p>ii. Xarelto; Danny McNatty, Janssen</p> <p>c. Public Testimony:</p> <p>i. Atisham Shakoor , MD</p> <p><b>Non-Supplemental Rebate Class Review: Magellan</b></p> <ol style="list-style-type: none"> <li>1. Antifungals, Oral</li> <li>2. Antifungals, Topical</li> <li>3. Beta Blockers</li> <li>4. BPH Agents</li> <li>5. Calcium Channel Blockers</li> <li>6. Steroids, Topical Low</li> <li>7. Steroids, Topical Medium</li> <li>8. Steroids, High</li> <li>9. Steroids, Topical Very High</li> </ol> <p><b><u>Executive Session</u></b></p>
3:15	Break
3:30	<b>Public Therapeutic Class Votes</b>
3:50	<b>PrEP – Truvada</b>
4:00	<b>Biktarvy- Lydia Neemann</b>
4:20	<p><b>Biosimilar Update:</b></p> <ol style="list-style-type: none"> <li>1.Retacrit: epoetin alfa-epbx – Epogen/Procrit</li> <li>2.Fulphilia: pegfilgrastim – Neulasta</li> <li>3.Glatopa: glatiramer acetate - Copaxone</li> </ol>
4:30	<p><b>New Drug Reviews</b></p> <ol style="list-style-type: none"> <li>1. Steglatro (Segluromet, Steglujan) – ertugliflozin, ertugliflozin/metformin, ertugliflozin/sitagliptin</li> <li>2. Zypitamag – pitavastatin magnesium</li> </ol>
5:00	<b>Meeting Adjourned</b>

**2018 Meeting Dates:**

- **October 22, 2018**

**2019 Meeting Dates:**

- **January 16, 2019**
- **April 10, 2019**
- **July 10, 2019**
- **October 16, 2019**